Patents Assigned to Bio-Technology General Corp.
-
Patent number: 6610520Abstract: A double-stranded cDNA molecule which includes DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human manganese superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eukaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase or analogs thereof which may then be recovered. By this invention, human MnSOD gene fragments from various plasmids may be ligated to yield a complete genomic human MnSOD gene fragment. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs, or treat inflammations.Type: GrantFiled: August 31, 1994Date of Patent: August 26, 2003Assignee: Bio-Technology General Corp.Inventors: Jacob R. Hartman, Yaffa Beck
-
Patent number: 6576659Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.Type: GrantFiled: December 5, 1997Date of Patent: June 10, 2003Assignee: Bio-Technology General Corp.Inventor: Don Fishbein
-
Publication number: 20020165266Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.Type: ApplicationFiled: October 22, 2001Publication date: November 7, 2002Applicant: Bio-Technology General Corp.Inventor: Don Fishbein
-
Patent number: 6361772Abstract: A double-stranded cDNA molecule which includes DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human manganese superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eukaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase or analogs thereof which may then be recovered. By this invention, human MnSOD gene fragments from various plasmids may be ligated to yield a complete genomic human MnSOD gene fragment. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs, or treat inflammations.Type: GrantFiled: July 25, 1996Date of Patent: March 26, 2002Assignee: Bio-Technology General Corp.Inventors: Jacob R. Hartman, Yaffa Beck
-
Patent number: 6211341Abstract: The present invention provides an antibody which specifically reacts with an epitope of a polypeptide comprising the amino acid sequence X-Y-CYS GLN GLU GLU GLU CYS PRO ASP PRO TYR LEU CYS SER PRO VAL THR ASN ARG CYS GLU CYS THR PRO VAL LEU CYS ARG MET TYR CYS LYS PHE TRP ALA LYS ASP GLU LYS GLY CYS GLU ILE CYS LYS CYS GLU GLU LEU CYS GLN ASN GLN ASN CYS THR LYS ASP MET LEU CYS SER SER VAL THR ASN ARG CYS ASP CYS GLN ASP PHE LYS CYS PRO GLN SER TYR CYS-Z (SEQ. ID NO. 1) wherein X is MET or absent; Y is 0-28 amino acids of the sequence LYS MET CYS TRP ASN LYS GLY CYS PRO CYS GLY GLN ARG CYS ASN LEU HIS ARG ASN GLU CYS GLU VAL ILE ALA GLU ASN ILE GLU, (SEQ. ID NO. 2) with the proviso that if part of the sequence is present, it is a carboxy-terminal part of the sequence including the carboxy-terminal GLU and wherein Val may be preceded by Gly; and Z is absent or all or a part of the sequence Pro110-Lys156 shown in FIG. 7 (SEQ. ID NO.Type: GrantFiled: January 11, 1999Date of Patent: April 3, 2001Assignee: Bio-Technology General Corp.Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
-
Patent number: 6121426Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: August 11, 1997Date of Patent: September 19, 2000Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Patent number: 6054291Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: June 9, 1997Date of Patent: April 25, 2000Assignee: Bio-Technology General Corp.Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
-
Patent number: 6030611Abstract: Improved methods for production of recombinant human superoxide dismutase and analogs thereof have been developed. Such superoxide dismutase or analogs may be used to catalyze the reduction of superoxide radicals thereby preventing or treating injury resulting from the presence of such superoxide radicals.Type: GrantFiled: May 26, 1995Date of Patent: February 29, 2000Assignee: Bio-Technology General Corp.Inventors: Marian Gorecki, Amnon Gonenne
-
Patent number: 6010875Abstract: Plasmids are provided which upon introduction into a suitable Eschericia coli host render the host capable of effecting expression of DNA encoding a desired naturally-occurring polypeptide or polypeptide analog thereof under the control of the deo P1-P2 promoter. Further plasmids are also provided which thermoinducibly direct expression of eucaryotic genes under the control of a .lambda. P.sub.L promoter and a thermolabile repressor protein present on the same plasmid under the control of a deo P1 promoter. These plasmids have been inserted into various hosts, some of which contain DNA encoding the repressor protein.Such plasmids may be used to produce polypeptides such as human copper/zinc superoxide dismutase, hMnSOD-hGPX fusion polypeptides, human manganese superoxide dismutase, human growth hormone, bovine growth, porcine growth, human growth hormone-apolipoprotein E fused polypeptides, apolipoprotein E and various fibronectin domains.Type: GrantFiled: July 25, 1996Date of Patent: January 4, 2000Assignee: Bio-Technology General Corp.Inventor: Meir Fischer
-
Patent number: 6008193Abstract: The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (von Willebrand Factor) GP1b binding domain. These polypeptides may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides to inhibit platelet aggregation.Type: GrantFiled: June 5, 1995Date of Patent: December 28, 1999Assignee: Bio-Technology General Corp.Inventors: Leonard Garfinkel, Tamar Richter
-
Patent number: 6001604Abstract: An improved and efficient process for the production of recombinant human insulin by folding of a proinsulin hybrid polypeptide is provided.Type: GrantFiled: November 12, 1997Date of Patent: December 14, 1999Assignee: Bio-Technology General Corp.Inventors: Jacob R. Hartman, Simona Mendelovitz, Marian Gorecki
-
Patent number: 5965383Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus-or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: March 24, 1995Date of Patent: October 12, 1999Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Patent number: 5948668Abstract: The subject invention provides a method of producing enzymatically active CPB which comprises treating a recombinant cell containing DNA encoding ProCPB, so that the DNA directs expression of the ProCPB, recovering from the cell the ProCPB so expressed, treating the recovered ProCPB under conditions permitting folding of the ProCPB, subjecting the folded ProCPB to enzymatic cleavage to produce enzymatically active CPB and purifying the enzymatically active CPB.Type: GrantFiled: January 13, 1997Date of Patent: September 7, 1999Assignee: Bio-Technology General Corp.Inventors: Jacob Hartman, Netta Fulga, Simona Mendelovitch, Marian Gorecki
-
Patent number: 5945304Abstract: Plasmids are provided which upon introduction into a suitable host render the host capable of effecting expression of DNA encoding a desired polypeptide under the control of an osmB promoter. Such plasmids may be used to produce polypeptides such as superoxide dismutases, acetylcholinesterase, growth hormones and hepatitis antigen.Type: GrantFiled: July 18, 1997Date of Patent: August 31, 1999Assignee: Bio-Technology General Corp.Inventor: Meir Fischer
-
Patent number: 5872147Abstract: The subject invention provides a method of treating a symptom associated with chronic obstructive pulmonary disease in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of improving functional capacity and/or pulmonary function in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.Type: GrantFiled: December 5, 1997Date of Patent: February 16, 1999Assignee: Bio-Technology General Corp.Inventor: Robert E. Bowen
-
Patent number: 5869616Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: April 8, 1997Date of Patent: February 9, 1999Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet, Jacob Hartman, Hadassa Shaked
-
Patent number: 5863534Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.Type: GrantFiled: June 6, 1995Date of Patent: January 26, 1999Assignee: Bio-Technology General Corp.Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
-
Patent number: 5858970Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.Type: GrantFiled: January 7, 1997Date of Patent: January 12, 1999Assignee: Bio-Technology General Corp.Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
-
Patent number: 5849702Abstract: The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (von Willebrand Factor) GP1b binding domain. These polypeptides, may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides, to inhibit platelet aggregation.Type: GrantFiled: June 5, 1995Date of Patent: December 15, 1998Assignee: Bio-Technology General Corp.Inventors: Leonard Garfinkel, Tamar Richter
-
Patent number: D403064Type: GrantFiled: June 28, 1995Date of Patent: December 22, 1998Assignee: Bio-Technology General Corp.Inventors: Yehuda Einav, Dror Eyal